Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C24H23F3N2O5. It features a benzo[d]isoxazole core substituted with propyl and trifluoromethyl groups, linked via an ether bridge to an indole moiety, which is further connected to an ethanoic acid group[1][6]. According to structure–activity relationship (SAR) studies and computer-aided drug design literature, this molecule acts as a potent agonist of peroxisome proliferator–activated receptor gamma (PPARγ), leading to full activation of the receptor in transactivation assays[6]. PPARγ agonists are primarily investigated for their roles in metabolic diseases such as type 2 diabetes mellitus due to their effects on glucose metabolism and insulin sensitivity. There is no evidence that this compound has been approved or marketed under any brand name.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-{5-[3-(7-propyl-3-trifluoromethylbenzo[d]isoxazol-6-yloxy)propoxy]indol-1-yl}ethanoic acid.